Menu
Enrolling by invitation NCT07346248

Postoperative Complications After Neoadjuvant Chemoradiotherapy or Short-course Radiotherapy and Total Neoadjuvant Treatment: a Multicentric Retrospective Cohort Study

Observational Adult Patients With Locally Advanced Rectal Cancer Indicated to Neoadjuvant Therapy and Surgery

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Chemoradiotherapy.
Who it may be relevant to
Registry conditions: Adult Patients With Locally Advanced Rectal Cancer Indicated to Neoadjuvant Therapy and Surgery. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The primary objective of the study is to compare the rate of postoperative complications between rectal cancer patients undergoing standard neoadjuvant chemoradiotherapy or short- course radiotherapy and patients receiving TNT. The secondary objectives of the study include the evaluation of treatment-related adverse reactions and postoperative complications in elderly patients receiving the treatments and the comparison of treatment-related adverse reactions and postoperative complications in patients receiving induction versus consolidation TNT.

Interventions

  • Procedure Chemoradiotherapy
    Comparing

Primary outcome measures

  • 90 days postoperative complications [Time frame: 12 months]
  • The primary endpoint of the study is the rate of 90-day postoperative complications between the study cohorts. [Time frame: 3 months]
Secondary outcome measures (8)
  • 90 days severe postoperative complications between the cohorts [Time frame: 12 months]
  • 90-day Comprehensive Complication Index [Time frame: 12 months]
  • Treatment-related adverse reactions [Time frame: 12 months]
  • Severe treatment-related adverse reactions [Time frame: 12 months]
  • 90-day postoperative complications between patients receiving neoadjuvant chemoradiotherapy,short-course radiotherapy, induction TNT, and consolidation TNT. [Time frame: 12 months]
  • Treatment-related adverse reactions between patients receiving neoadjuvant chemoradiotherapy,short-course radiotherapy, induction TNT, and consolidation TNT [Time frame: 12 months]
  • The rate of 90-day postoperative complications between the two cohorts in a sub-population of elderly patients [Time frame: 12 months]
  • The rate of treatment-related adverse reactions between the study cohorts in a sub-population of elderly patients [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • Patients with locally advanced (T2N+, T3N+, T4N0, or T4N+) rectal adenocarcinoma who underwent neoadjuvant chemoradiotherapy or short-course radiotherapy or TNT and surgery between January 2016 and January 2025;
  • Patients who underwent restorative or non-restorative surgery;
  • Patients undergoing open, laparoscopic, or robotic intervention.

Exclusion criteria

  • Patients who underwent non-operative management after neoadjuvant treatment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Italy · 1 center
  • IRCCS Humanitas Research Hospital — Rozzano

Identifiers

NCT: NCT07346248 · 5019

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗